K+10
Clinical safety rating: caution
Comprehensive clinical and safety monograph for K+10 (K+10).
Potassium ion replacement; essential for maintenance of intracellular tonicity, nerve impulse transmission, cardiac and skeletal muscle contraction, and acid-base balance.
| Metabolism | Primarily excreted unchanged by the kidneys (90%); small amount excreted in feces. Not metabolized. |
| Excretion | Potassium is primarily excreted via the kidneys (approximately 90%) with the remainder lost in feces (via colonic secretion). In patients with normal renal function, urinary potassium excretion accounts for >90% of elimination. Fecal excretion is minimal (≤10%) but increases in renal impairment. |
| Half-life | Potassium does not have a true elimination half-life as it is an endogenous ion under homeostatic control. However, intravenously administered potassium has a distribution half-life of approximately 1-1.5 hours and a slow terminal phase reflecting cellular redistribution and eventual excretion. Clinical context: The apparent half-life is highly dependent on renal function and body stores. |
| Protein binding | Potassium is not significantly bound to plasma proteins. It is essentially free in plasma (0% protein binding). |
| Volume of Distribution | Vd: Approximately 0.5 L/kg (range 0.4-0.6 L/kg). This reflects distribution primarily into the extracellular fluid compartment, with subsequent slow equilibration into the intracellular space. Clinical meaning: The Vd is small, indicating that potassium remains largely in the ECF and is not extensively tissue-bound initially. |
| Bioavailability | Oral: Potassium chloride solutions have bioavailability near 100% as they are completely absorbed. Solid oral formulations (tablets, capsules) have variable bioavailability depending on dissolution and release characteristics; enteric-coated products may have reduced bioavailability (80-90%). Intravenous: 100%. |
| Onset of Action | Intravenous: Immediate (seconds to minutes) when given as a bolus or rapid infusion for life-threatening hypokalemia. Oral: Onset of effect is within 1-2 hours for potassium chloride solutions, but may be delayed to 3-6 hours for enteric-coated or slow-release formulations. |
| Duration of Action | Intravenous: Duration of clinical effect (e.g., ECG normalization, serum K+ rise) is transient, lasting minutes to a few hours depending on dose and redistribution. Oral: Effect lasts 4-6 hours for immediate-release formulations; extended-release preparations maintain serum levels for 8-12 hours. Note: Duration is influenced by ongoing losses and renal clearance. |
IV: 10 mEq potassium chloride infused at a rate not exceeding 10 mEq/hour via peripheral line; maximum 20 mEq/hour via central line with continuous ECG monitoring. Oral: 20-40 mEq per day in divided doses; maximum 100 mEq per day.
| Dosage form | TABLET, EXTENDED RELEASE |
| Renal impairment | GFR > 50 mL/min: no adjustment. GFR 10-50 mL/min: reduce dose by 50%; monitor serum potassium frequently. GFR < 10 mL/min: contraindicated unless serum potassium < 5.0 mEq/L and dialysis available. |
| Liver impairment | No specific Child-Pugh dose adjustment required; monitor serum potassium and acid-base status due to risk of hyperkalemia in cirrhosis. |
| Pediatric use | IV: 0.5-1 mEq/kg/dose up to 10 mEq per dose, infused at ≤0.5 mEq/kg/hour; maximum 1 mEq/kg/hour with cardiac monitoring. Oral: 1-2 mEq/kg/day in divided doses; maximum 3 mEq/kg/day. Use with caution in neonates. |
| Geriatric use | Initiate at low end of adult dosing (e.g., 10-20 mEq/day oral); reduce infusion rate to ≤10 mEq/hour IV; monitor renal function and serum potassium closely due to age-related decreased GFR and increased sensitivity. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for K+10 (K+10).
| Breastfeeding | Potassium is a normal component of human milk; supplementation unlikely to cause harm. M/P ratio not established but assumed to be ~1 due to passive distribution. Use caution with high doses (e.g., 10 mEq) as theoretical risk of hyperkalemia in infant if maternal levels elevated. Monitor infant for signs of hyperkalemia only if maternal dose high or renal impairment. |
| Teratogenic Risk | Potassium chloride (K+10) is FDA pregnancy category C. No adequate well-controlled studies in pregnant women. In first trimester, no evidence of teratogenicity from animal studies; however, high doses may cause maternal hyperkalemia with potential fetal effects due to altered maternal physiology. In second and third trimesters, risk primarily from maternal electrolyte imbalance. Avoid in severe hyperkalemia as it may cross placenta. |
■ FDA Black Box Warning
Potassium supplements can cause hyperkalemia and cardiac arrest. Use with extreme caution in patients with conditions predisposing to hyperkalemia. Monitor serum potassium levels and ECG regularly.
| Serious Effects |
Hyperkalemia, severe renal impairment with oliguria or azotemia, untreated Addison's disease, acute dehydration, heat cramps, and patients receiving potassium-sparing diuretics or aldosterone antagonists.
| Precautions | Risk of hyperkalemia, especially with renal impairment, diabetes, or concurrent use of potassium-sparing diuretics or ACE inhibitors. Avoid rapid intravenous administration. Use with caution in patients with cardiac disease or those receiving digitalis. |
Loading safety data…
| Fetal Monitoring | Monitor maternal serum potassium levels periodically, particularly during prolonged therapy or in conditions affecting potassium balance (e.g., preeclampsia, renal impairment). Assess renal function and cardiac monitoring if high doses or parenteral use. Fetal assessment not specifically required unless maternal hyperkalemia develops; consider fetal heart rate monitoring if severely elevated potassium (>6.0 mEq/L) due to risk of arrhythmias. |
| Fertility Effects | No known direct effects on human fertility. Potassium is an essential electrolyte; supplementation corrects deficiency which may improve overall health but does not enhance fertility. High doses may cause metabolic disturbances that could indirectly affect reproductive function, but no established data. |